RegCell Co.,Ltd.

Regcell is a university-originated venture company and aims to develop novel immunotherapies for immunological diseases and cancer by targeting regulatory T cells, which are specialized for immune suppression.

Based based in Tokyo, Japan, RegCell Co.,Ltd. works in medical engineering & biotechnology.

Profile

Regcell Co., Ltd., which was founded in January, 2016, aims to develop novel therapeutic technologies for autoimmune disease, graft-versus-host disease, allergy and cancer through augmenting or suppressing immune responses by targeting regulatory T (Treg) cells. Two projects are currently in progress. One is to convert disease-mediating T cells into functionally stable Treg cells in vitro and use them as cell therapy to treat autoimmune and other inflammatory diseases. The other is to explore small compounds that are specifically able to deplete Treg cells in tumor tissues and thereby enhance anti-cancer immunity.

Its activity falls under medical engineering & biotechnology; the profile below is assembled from public directory data.

Its base of operations is Tokyo, Japan.

The company is listed at the J-Startup selected company stage of development.

Website: www.regcell.jp